#non-nucleoside reverse transcriptase inhibitor

People who used long-acting Cabenuva preferred the injections over their previous daily oral regimen.

Resistance to four HIV drug classes is tied to high risk of disease and death.

People contracting HIV are increasingly acquiring strains that are resistant to antiretrovirals (ARVs).

Celebrating 20 years of effective HIV treatment

Here’s a timeline of the highlights.

HIV treatment taken only every two months is moving closer to reality.

ViiV Healthcare is beginning Phase III trials of the integrase inhibitor Tivicay and the non-nucleoside reverse transcriptase inhibitor Eduran...

Merck’s next-generation NNRTI doravirine (MK-1439) suppresses HIV as well as Sustiva (efavirenz) and leads to half the rate of side effects.